IGF-BP7, human recombinant

IGF-BP7, human recombinant is available at Gentaur for Next week delivery.

Plays a role in skeletal myogenesis by binding to IGF

Biomolecule/Target: IGF-BP7

Alternates names: Insulin-like growth factor binding protein-7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBPrP1)

Synonyms: Insulin-like growth factor binding protein-7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBPrP1)

Background Information: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in acetic acid to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

NCBI Gene Symbol: IGFBP7

Gene ID: 3490

NCBI Accession: Q16270